ALK and cancer: We plated the established (pure cancer cell) cell lines of EGFR mutant or ALK-translocated NSCLCs into 384-well plates and compared their sensitivity to an EGFR or ALK inhibitor, respectively, using CellTiter-Glo or the immunofluorescence-based method (Figure 1).